Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson’s Disease Patients over a Decade in Singapore
Table 1
Patient characteristics and treatment based on the year of diagnosis.
Entire cohort n = 230
2007 cohort n = 83
2017 cohort n = 147
value
Mean (SD) age, years
66.7 (10.3)
66.4 (10.1)
66.9 (10.5)
0.737
Male, n (%)
131 (57.0)
48 (57.8)
83 (56.5)
0.840
Mean (SD) HY stage
2.3 (0.7); n = 222
2.4 (0.7); n = 76
2.2 (0.6); n = 146
0.196
Mean (SD) duration of illness, months
65.5 (57.0); n = 228
59.7 (56.4); n = 82
68.6 (57.3); n = 146
0.246
Rest tremor present
125 (61.3); n = 204
44 (69.8); n = 63
81 (57.4); n = 141
0.093
Monotherapy, n (%)
196 (85.2)
70 (84.3)
126 (85.7)
0.778
Treatment, n (%)
LD
Total
166 (72.2)
55 (66.3)
111 (75.5)
0.133
Monotherapy
151 (65.7)
53 (63.9)
98 (66.7)
Ergot DA
Total
19 (8.3)
16 (19.3)
3 (2.0)
<.001
Monotherapy
10 (4.3)
10 (12.0)
0 (0.0)
Nonergot DA
Total
18 (7.8)
4 (4.8)
14 (9.5)
0.202
Monotherapy
10 (4.3)
1 (1.2)
9 (6.1)
MAOBI
Total
48 (20.9)
11 (13.3)
37 (25.2)
0.033
Monotherapy
22 (9.6)
4 (4.8)
18 (12.2)
Anticholinergic
Total
14 (6.1)
10 (12.0)
4 (2.7)
0.004
Monotherapy
3 (1.3)
2 (2.4)
1 (.07)
Mean (SD) LED, mg/day
204 (113)
198 (106)
207 (117)
0.566
DA, dopamine agonist; HY, Hoehn and Yahr; LD, levodopa; LED, levodopa equivalent dose; MAOBI, monoamine oxidase type B inhibitor; SD, standard deviation. Combination and monotherapy.
